Why Creso Pharma Ltd shares rocketed 13% higher today

In early trade one of the best performers on the market has been the Creso Pharma Ltd (ASX: CPH) share price.

At the time of writing the diversified cannabis company’s shares are just a fraction away from an all-time high and up almost 13% to 88 cents.

Incredibly this means that Creso Pharma’s shares have now rallied a massive 60% since the start of the month.

What happened?

As well as benefitting from improved investor sentiment and its exposure to Canada’s recreational cannabis market, Creso Pharma’s shares have taken off today following another positive announcement.

According to the release, Creso Pharma and global pharmaceutical animal health giant Virbac have launched its anibidiol product in Switzerland through veterinary practices.

Anibidiol is a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol, the non-psychoactive substance of the hemp plant. The product supports companion animals’ immune systems, its natural defences, and contributes to balanced behaviour.

The global animal health market is estimated to be worth US$30 billion per annum and is expected to continue to grow rapidly for some time to come. If Creso Pharma and rival Cannpal Animal Therapeutics Ltd (ASX: CP1) can grab a slice of this market, they’ll certainly do very well from it.

While at this stage it is only being marketed in Switzerland, I believe there is a chance it could end up going global eventually and even stocked in Australia by veterinary practices operated by National Veterinary Care Ltd (ASX: NVL) and Greencross Limited (ASX: GXL).

Should you invest?

Creso Pharma is certainly one of the best-positioned pot stocks on the Australian market in my opinion and has several potentially lucrative revenue streams.

While it is still a little early for me to invest, I’ll be watching on with interest to see how things develop over the coming months.

Finally, here are three exciting small-cap shares I would buy today.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We're living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That's why at The Motley Fool we've been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We've found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Greencross Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.